BFM
TTPH

Boothbay Fund Management’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Boothbay Fund Management’s Portfolio TTPH Stock Details TTPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-3,180
Closed -$453K – 841
2017
Q2 		$453K Buy
3,180
+2,092
+192% +$323K 0.09% 273
2017
Q1 		$200K Buy
+1,088
New +$122K 0.04% 606

Other funds holding TTPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Boothbay Fund Management's TTPH Position: Q3 2017 in Review

Boothbay Fund Management sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q3 2017, closing a stake of 3,180 shares — an estimated $453K sold.

Boothbay Fund Management first reported a position in TTPH in Q1 2017 and held it in 2 quarters. The position peaked at $453K in Q2 2017. 94 funds tracked by Wall St. Rank hold TTPH as of Q3 2017.

  • Boothbay Fund Management reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • Boothbay Fund Management sold 3,180 Tetraphase Pharmaceuticals, Inc. shares in Q3 2017, an estimated $453K.
  • Boothbay Fund Management first reported a position in Tetraphase Pharmaceuticals, Inc. in Q1 2017 and held it in 2 quarters.
  • Boothbay Fund Management's Tetraphase Pharmaceuticals, Inc. position peaked at $453K in Q2 2017.
  • 94 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q3 2017.

Based on Boothbay Fund Management's 13F filing for Q3 2017, filed 14 Nov 2017.